Low HDL Cholesterol is Associated with Reduced Bleeding Risk in Patients who Underwent PCI: Findings from the PRACTICE Study
Thrombosis and Haemostasis · 01.02.2025 · 125 (02) · 178-187
DOI: 10.1055/a-2104-1693 ↗Kurz gefasst
Fachartikel in der Zeitschrift Thrombosis and Haemostasis, erschienen am 01.02.2025. Verfasst von Ying-Ying Zheng und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, First Affiliated Hospital of Xinjiang Medical University, Urumqi, P.R. China. Hauptthemen laut MEDLINE: Percutaneous Coronary Intervention, Cholesterol, HDL, Coronary Artery Disease, Hemorrhage. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Data Center of Management Science, National Natural Science Foundation of China - Peking University.
Abstract (Originalsprache)
Background
We sought to examine the dose–response relationship between high-density lipoprotein cholesterol (HDL-C) and bleeds in coronary artery disease (CAD) patients who underwent percutaneous coronary intervention (PCI).
Methods
All the 15,250 participants were from the Personalized Antiplatelet Therapy According to CYP2C19 Genotype in Coronary Artery Disease (PRACTICE) study, which is a large, single-center, prospective cohort study based on case records and a follow-up registry performed in the First Affiliated Hospital of Xinjiang Medical University from December 2016 to October 2021. We divided all the patients into five groups according to their HDL-C levels: the ≤35 mg/dL group (n = 4,732), 35 to 45 mg/dL group (n = 6,049), 45 to 55 mg/dL group (n = 2,826), 55 and 65 mg/dL group (n = 1,117), and >65 mg/dL group (n = 526). The incidence of bleeds, mortality, ischemic events, and net adverse clinical events (NACEs) among the five groups was compared.
Results
A total of 713 bleeds, 1,180 ischemic events, 456 deaths, and 1,893 NACEs were recorded during the up to 60-month follow-up period. After adjusting for confounders, we observed a nonlinear relation for bleeds, with the highest risk at intermediate HDL-C levels (45–55 mg/dL). We also identified a dose–response relationship for ischemic events. A threshold value of HDL-C ≤35 mg/dL (adjusted hazard ratio = 0.560, 95% confidence interval: 0.360–0.872, p = 0.010) was associated with a decreased risk for bleeds in the multivariable Cox regression model. The results were consistent in multiple sensitivity analyses and propensity score-matching analysis.
Conclusion
In the present study, a nonlinear association was identified between HDL-C levels and bleeds in CAD patients who underwent PCI, with a higher risk at intermediate levels. However, further multicenter studies are warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, First Affiliated Hospital of Xinjiang Medical University, Urumqi, P.R. China.
- Key Laboratory of High Incidence Disease Research in Xinjiang (Xinjiang Medical University), Ministry of Education, The People's Republic of China, Urumqi, P.R. China.
ORCID-Profile: Xiang Ma
Förderung
- Data Center of Management Science, National Natural Science Foundation of China - Peking University
Zitieren
APA
Zheng, Y. Y., Wu, T. T., Hou, X. G., Yang, Y., Yang, H. T., Pan, Y., Xiu, W. J., Ma, X., Ma, Y. T., Yang, X. L., & Xie, X. (2025). Low HDL Cholesterol is Associated with Reduced Bleeding Risk in Patients who Underwent PCI: Findings from the PRACTICE Study. Thrombosis and Haemostasis, 125(02), 178-187. https://doi.org/10.1055/a-2104-1693
Vancouver
Zheng YY, Wu TT, Hou XG, Yang Y, Yang HT, Pan Y, et al. Low HDL Cholesterol is Associated with Reduced Bleeding Risk in Patients who Underwent PCI: Findings from the PRACTICE Study. Thrombosis and Haemostasis. 2025;125(02):178-187. doi:10.1055/a-2104-1693
BibTeX
@article{Zheng2025,
author = {Zheng, Ying-Ying and Wu, Ting-Ting and Hou, Xian-Geng and Yang, Yi and Yang, Hai-Tao and Pan, Ying and Xiu, Wen-Juan and Ma, Xiang and Ma, Yi-Tong and Yang, Xin-Ling and Xie, Xiang},
title = {Low HDL Cholesterol is Associated with Reduced Bleeding Risk in Patients who Underwent PCI: Findings from the PRACTICE Study},
journal = {Thrombosis and Haemostasis},
year = {2025},
volume = {125},
number = {02},
pages = {178--187},
doi = {10.1055/a-2104-1693}
}
EUVIMED